Results 101 to 110 of about 2,507,641 (307)

Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.

PLoS ONE
BackgroundCurrent treatment recommendations for resectable or borderline pancreatic carcinoma support upfront surgery and adjuvant therapy. However, neoadjuvant therapy (NT) seems to increase prognosis of pancreatic carcinoma and come to everyone's ...
Lu Huan, Fucai Yu, Ding Cao, Hantao Zhou, Maoling Qin, Yang Cao   +5 more
doaj   +1 more source

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies

, 2022
SIMPLE SUMMARY: The response to neoadjuvant treatment is strongly associated with the clinical outcome of breast cancer patients, especially in the HER2-positive subtype of the disease.
Lars Hanker, Achim Rody, Fehm, Tanja, Maggie Banys-Paluchowski, Tanja Fehm, Laura Brus, Kopperschmidt, Valeria, Hanker, Lars, Brus, Laura, Eugen Ruckhaeberle, Krawczyk, Natalia, Rody, Achim, Natalia Krawczyk, Valeria Kopperschmidt, Ruckhaeberle, Eugen, Banys-Paluchowski, Maggie   +15 more
core   +1 more source

Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer

Advanced Science, EarlyView.
This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang   +9 more
wiley   +1 more source

A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road

For most patients with advanced thymic epithelial tumors (TETs), a complete resection is a strong indicator of a better prognosis. But sometimes, primary surgery is unsatisfactory, and preoperative therapy is needed to facilitate complete resection ...
Zhitao Gu, Xiuxiu Hao, Fenghao Yu, Xuefei Zhang, Ning Xu, Changlu Wang, Yizhuo Zhao, Teng Mao, Wentao Fang   +8 more
core   +1 more source

GM‐CSF Promotes Neutrophil PD‐L1 Expression Through the VEGFR‐2/STAT6/CSF2 Signaling Axis in Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu, Yuanhe You, Yiyi Zhang, Yibin Dai, Xinyu Zhou, Yong Fu, Xi Lu, Yingying Huang, Zhihang Zhou, Ronghui Xia, Wutong Ju, Zhaoqi Yuan, Laiping Zhong, Tongchao Zhao   +13 more
wiley   +1 more source

Patient reported outcomes after neoadjuvant therapy for rectal cancer: A systematic review

, 2014
Neoadjuvant therapy followed by total mesorectal excision is standard of care for locally advanced rectal cancer. However, this approach has been previously shown to be associated with high rate of morbidity and it may have a negative effect on patients’
LOTTO, LORELLA, GAVARUZZI, TERESA, GIANDOMENICO, FRANCESCA, PUCCIARELLI, SALVATORE, PERIN, ALESSANDRO   +4 more
core   +2 more sources

Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy

Advanced Science, EarlyView.
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu, Qishuai Chen, Yan Ma, Yang Liu, Xianing Dong, Wenjuan Wei, Jianxin Du, Shusheng Qiu, Maojin Tian, Peiqing Zhao   +9 more
wiley   +1 more source

Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma

Cancer Medicine
Introduction This study aimed to compare the long‐term effects of neoadjuvant therapy and upfront surgery on overall survival (OS) and progression‐free survival (PFS) in patients with resectable pancreatic ductal adenocarcinoma (PDAC).
Kyung In Shin, Min Sung Yoon, Jee Hoon Kim, Won Joon Jang, Galam Leem, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Ho Kyoung Hwang, Chang Moo Kang, Seung‐seob Kim, Mi‐Suk Park, Hee Seung Lee, Seungmin Bang   +14 more
doaj   +1 more source

Post-Neoadjuvant Therapy [PDF]

Breast Care, 2019
Michael Untch, Andreas Schneeweiss, David Krug, Thorsten Kühn, Sibylle Loibl   +4 more
openaire   +2 more sources

Neoadjuvant-Based Triple Therapy for Hepatocellular Carcinoma with Type I/II Portal Vein Tumor Thrombosis [PDF]

Guimin Hou,1,* Feng Zhang,1,* Xielin Feng,1 Yan Chen,2 Jinliang Zhang,1 Haiqing Wang1 1Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of
Zhang F, Zhang J, Feng X, Chen Y, Wang H, Hou G   +5 more
core